Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Sphingolipid metabolism

  • Home
  • Sphingolipid metabolism
Targeting SMPD1-Driven Sphingolipid Metabolism to Disrupt KRAS Signaling in Pancreatic Ductal Adenocarcinoma
Posted inGastroenterology news Oncology

Targeting SMPD1-Driven Sphingolipid Metabolism to Disrupt KRAS Signaling in Pancreatic Ductal Adenocarcinoma

Posted by MedXY By MedXY 07/08/2026
This study reveals that dysregulated sphingolipid metabolism via SMPD1 supports KRAS-driven pancreatic cancer progression, identifying SMPD1 as a promising therapeutic target in pancreatic ductal adenocarcinoma.
Read More
  • Expanding the Horizon of Simultaneous Liver-Kidney Transplantation: Leveraging DCD Donors with Machine Perfusion Technologies
  • Adjunctive SGLT2 Inhibitors with Progestins Reduce Endometrial Cancer Risk in Benign Uterine Conditions: Insights from a Large Real-World Study
  • Labour Progression Differences Between IVF/ICSI and Spontaneous Pregnancies Following Induction: Insights from a Matched Cohort Study
  • Evaluating Early Home Removal of Urinary Catheters After Urogynecologic Surgery: A Randomized Controlled Trial
  • Evaluation of Postpartum Glucose Tolerance Test Results Based on Criteria and Timing: Implications for Diagnostic Accuracy and Clinical Practice
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in